Gut microbiota‐derived synbiotic formula (SIM01) as a novel

Full article: A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines

Frontiers The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial - The Lancet Infectious Diseases

PDF) Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)

Synbiotic may lower risk of Covid complications in vulnerable

Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study - Zhang - 2022 - Journal of Gastroenterology and Hepatology - Wiley Online Library

Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study - Zhang - 2022 - Journal of Gastroenterology and Hepatology - Wiley Online Library

Siew NG, Professor (Full), MBBS (Lon), FRCP (Lond, Edin), PhD (Lond), FHKCP, FHKAM (Med), The Chinese University of Hong Kong, Hong Kong, CUHK, Department of Medicine and Therapeutics

Probiotics for immunomodulation in prevention against respiratory viral infections with special emphasis on COVID-19